Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study” and a case report of glucagon-like peptide-1 receptor agonist–induced bullous pemphigoid - 16/05/19
Doi : 10.1016/j.jaad.2019.01.086
Zachary Schwager, MD ⁎ 
, Anar Mikailov, MD, Adam D. Lipworth, MD
, Anar Mikailov, MD, Adam D. Lipworth, MD Division of Dermatology, Lahey Hospital and Medical Center, Burlington, Massachusetts
∗Correspondence to: Zachary Schwager, MD, Division of Dermatology, Lahey Hospital and Medical Center, 67 S Bedford Rd, Burlington, MA 01803Division of DermatologyLahey Hospital and Medical Center67 S Bedford RdBurlingtonMA01803
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 80 - N° 6
P. e189-e190 - juin 2019 Retour au numéro
Article précédent
- Reply to: “Comment on ‘Anti-aging effects of ingenol mebutate for patients with actinic keratosis' and phenol-croton oil peelings”
- Miri Kim, Yujin Jung, Jongsic Kim, Seo-won Jeong, Yu Ri Woo, Hyun Jeong Park
- Reply to: “Comment on ‘Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study’ and a case report of glucagon-like peptide-1 receptor agonist–induced bullous pemphigoid”
- Outi Varpuluoma, Kaisa Tasanen, Laura Huilaja
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?